This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only
One of the strongest performing biopharmaceutical stocks this year is Evolus (EOLS). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then its […]